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Introduction 
TLR7 agonist conjugation 
 
 
 
 
 
 
 
 
 
The earliest definition of vaccine adjuvants describes them as components that are 
added to vaccine antigens to make them more immunogenic, but this definition is quite 
imprecise due to the broad variety of candidates available (O'Hagan and De Gregorio 
2009). Nowadays the in vivo adjuvant effect can be divided into two principal 
components: delivery and immune potentiation. Delivery systems localize antigens and 
target to the appropriate cell types of the innate immune system and can also be 
optimized for immune potentiator targeting. Immune potentiators directly activate 
innate immune cells providing the pro-inflammatory context for antigen recognition 
(O'Hagan and Valiante 2003) and to this class belong some molecules with agonistic 
activity on the toll like receptors.  
Toll-like receptors (TLRs) are a set of conserved cellular receptors that play an 
important role in the recognition of microbial pathogens and in initiating the host innate 
immune response. These receptors recognize distinct molecular components of invading 
pathogens, such as cell wall structures and nucleic acids. The discovery that endogenous 
ligands as well as synthetic small molecules can activate certain TLR pathways has 
generated tremendous interest in the development of new therapeutics drugs for 
infectious diseases (Stanley 2002). 
 
 
 
 
 
Fig.1 Different Toll like receptors (TLRs) and their natural agonists 
  
Some synthetic compounds with an agonistic activity on the TLR7 belongs to different 
classes as imidazoquinolinamines (Miller, Gerster et al. 1999), 8-oxo-3-deazapurine 
(Tran, Pryde et al. 2011) and 6-amino-9-benzyladenine (Jin, Wu et al. 2006). They are 
generically called SMIPs (small molecules immuno-potentiators) because are able to 
modulate the immune response through immunoglobulin production (Othoro, Johnston 
et al. 2009), interferon and cytokines synthesis (Hemmi, Kaisho et al. 2002). These 
compounds have potential to be used in different pathologies from cancer (Johnston and 
Bystryn 2006; Johnston, Zaidi et al. 2007) to parasitic infection (Othoro, Johnston et al. 
2009) and as novel immunemodulators (Dockrell and Kinghorn 2001), to increase 
potency of recombinant proteins in vaccines development (Tomai and Vasilakos 2011). 
 
 
 
 
 
Fig.2 SIMPs TLR7 structures known in the literature  
 
Several studies demonstrated that when Imiquimod formulated as cream for dermal 
application (Aldara®) (Tomai and Vasilakos 2011), locally administered after 
subcutaneous immunization with ovalbumin (OVA), was able to enhance the anti-OVA 
antibody response of a 10-fold compared to mice that were not treated with imiquimod 
(Johnston and Bystryn 2006); same results have been found in mice subcutaneous 
immunized with Plasomodium falciparum circumsporozoite peptides and then topically 
treated with Aldara (Othoro, Johnston et al. 2009) (Fig.3) .This enhancement effect was 
probably connected with the slow release at the injection site of Imiquimod from the 
cream formulation, that allowed a kind of simultaneous presentation of the TLR agonist 
and the antigen (Ag) to the dentritic cells (DCs) (Ahonen, Doxsee et al. 2004). 
 
 
 
 
 
Fig.3 Immunogenicity enhancement due to the co-administration of OVA plus 
Imiquimod (OVA/IMIQ) in comparison to OVA alone (OVA), liposome encapsulated 
OVA (OVA/LIP) and E.G7-OVA cells that synthesize OVA constitutively and present 
OVA derived peptides on the cell surface within the MHC I context. 
 
Another way that allowed evaluating the co-delivery of TLR7 agonist and Ag were 
liposomes and nanoparticles; in these systems, the effect is due to the encapsulation of 
TLR agonist and Ag in the same particle that is phagocyted by the APCs (antigen 
presenting cells). The encapsulation of Resiquimod (also called R-848, a TLR7 agonist) 
into liposomes further enhances the OVA antibody response in comparison with the 
simple administration of OVA+3M-019 (Johnston, Zaidi et al. 2007) (Fig.4).  
Liposomes and nanoparticles due to their particulate structure, after phagocitosis from 
the immune system cells, through a co-delivery effect are able to co-localizate the TLR 
agonist and the Ag (O'Hagan and Valiante 2003; Valmori, Souleimanian et al. 2007). In 
these delivery systems the components interaction is only due to their physical 
 
 
 
properties without a chemical bound TLR agonist and Ag (Foged, Arigita et al. 2004; 
Oyewumi, Kumar et al. 2010). 
 
Fig.4 Relative OVA specific IgG subclass responses to immunization. Individual sera 
collected from mice 1 week after the fourth immunization were analyzed by ELISA for 
specific IgG subclasses antibodies to OVA using a mouse subtyping kit. Each bar 
represents the mean absorbance and the standard deviation of triplicate wells of sera 
collected from eight mice for all groups except OVA/Lip which consisted of six mice 
 
These studies suggested the possibility that the immune system requires a synchronized 
exposure of the DCs to the TLR agonist; it appeared that TLR activation alone is not 
sufficient to drive certain types of adaptive responses, such as CD8
+ 
T cells, therefore 
TLR-7/8 agonists may need to be coupled with other stimuli for optimal activity (Oh 
and Kedl 2010). 
This hypothesis was supported by some mechanicistic studies on DCs that showed how 
the efficiency of presenting antigens from phagocytosed cargo was dependent on the 
presence of TLR ligands within the cargo (Blander and Medzhitov 2006) and the mode 
of antigen delivery into DCs coupled with the right type of signal. This can impact not 
 
 
 
only the co-stimulatory context, in which the antigen is presented to naive T cells, but 
MHC-II presentation of the antigen and formation of the T-cell receptor ligand itself 
(Blander 2007). 
The effect of the direct co-localization TLR7 agonist and Ag has been already showed 
by different works from Wille-Reece et al. in mice (Wille-Reece, Wu et al. 2005) and in 
non human primates (Wille-Reece, Flynn et al. 2005), by UV-catalyzed conjugation of 
the TLR7/8 agonist 3M-012 (structurally similar to R848) to the Gag protein from HIV, 
that resulted in enhanced Th1 and CD8
+
 T cell responses, demonstrating that the 
TLR7/8 agonist could be a useful adjuvant to increase the cytokines production in vivo 
if administered as a protein conjugate. The increased efficiency of DCs activation rather 
than prolonged duration of Ag presentation have been suggested to be the mechanism 
by which the Ag-TLR7/8 conjugate enhances T cell responses in vitro (Wille-Reece, 
Flynn et al. 2005; Wille-Reece, Wu et al. 2005) (Fig.5).  
 
 
 
 
 
 
 
 
 
Fig.5 A) IFN and B) IL-2 producing cells and are increased after immunization with 
HIV Gag protein and a TLR7/8 agonist or CpG ODN. NHPs were immunized four 
times at 4-week intervals with HIV Gag protein, with or without CpG ODN, TLR7/8, or 
TLR8 agonist. An additional group was immunized in a similar manner with HIV Gag 
protein conjugated to the TLR7_8 agonist (Gag-TLR7/8 conjugate). PBMCs were 
harvested at various times post immunization, and the frequencies of IFN and IL-2 
producing cells were measured 
 
Another study made from Wu et al. showed the effect of the conjugation of a TLR7 
ligand (UC-1V150) to mouse serum albumine (MSA) after its linkage with an idrazide 
linker (SANH) to obtain the activated MSA-SANH that can be conjugated via reductive 
ammination to the TLR7 ligand. The effect of the TLR7 conjugation to MSA induced a 
Th1 and Th2 antigen specific response (Chan, Hayashi et al. 2009) and extended mice 
survival after challenge with Bacillus anthracis spores (Wu, Hayashi et al. 2007). 
 
 
 
Wu et al. showed the effect of the conjugation of a TLR7 ligand (UC-1V150) to mouse 
serum albumine (MSA) after its linkage with an idrazide linker (SANH) to obtain the 
activated MSA-SANH that can be conjugated via reductive ammination to the TLR7 
ligand. This study displayed a deeper analytical characterization, developed to estimate 
the conjugation ratio Ag:TLR7 agonist (1:5) and the average molecular weight. 
The authors decided to compare the conjugate UC-1V150/MSA versus the UC-1V150 
alone; the doses used for the immunizations were calculated on a molar base; due to the 
conjugation ratio 5:1, 3.8 nmols of UC-1V150/MSA was equal to 19 mols of UC-
1V150 and not 3.8 nmols as used (Wu, Hayashi et al. 2007). 
 
 
 
Fig.6 Preclinical efficacy of UC-1V150/MSA in pulmonary infectious diseases. Age-
matched female A/J mice were administered i.n. saline only or saline containing MSA 
(amount equivalent to UC-1V150/MSA), UC-1V150, or UC-1V150/MSA at 0.75 nmol 
per mouse 1 day before B.anthracis infection,and survival was followed for 13 days. 
 
 
 
 
 
 
Looking at these promising results, we decide to evaluate the effect of a TLR agonist 
conjugate on a model protective antigen and investigate its impact on the 
immunogenicity and protection in a pre-clinical model, using a SMIP TLR7 agonist 
(named TLR7aR) with a mild and selective conjugation reaction.   
The previous works done on TLR agonist bioconjugation were highly focused on the 
immunological response, but they lack in terms of serological analysis and impact on 
protection with an unformulated system, through simple administration in a 
physiological buffer (Wille-Reece, Flynn et al. 2005; Wille-Reece, Wu et al. 2005; Wu, 
Hayashi et al. 2007; Kastenmuller, Wille-Reece et al. 2011). 
With this proof of concept we want to asset an integrated and comprehensive approach 
for TLR7 agonist conjugation, characterization and formulation and to investigate the 
impact of Ag and TLR agonist co-localization on the immunogenicity applied on a 
model protein antigen when it is alum formulated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and methods 
 
 
 
 
 
 
 
 
 
 
 
 
Conjugation reaction 
 
The recombinant pilus subunits RrgB clade I His-tag form (molecular mass 66kDa) 
from  S. pneumoniae serotype 4 TIGR4 strain, was expressed in Escherichia coli and 
purified in soluble form by affinity chromatography on His-Trap high-performance 
column (GE Healthcare) at 3.92 mg/ml in 50 mM Tris and 100 mM NaCl, pH 8.0. 51 µl 
of protein solution were mixed with a 1 µl of a DMSO solution of the TLR7aR at a 
concentration of 117 mM in DMSO (38000 fold excess) in a PCR tube. The TLR7aR 
was internally synthesized and it had a molecular weight of 1484.77 a.m.u.; the linker 
lenght is 71.81 Å (calculated for the minimum energy structure). The lysine derivative 
of the agonist showed on HEK-293 TLR7 reporting line cell a value of EC50=0.35 uM 
(equal to 110% of Resiquimod) and no activation on HEK-293 TLR8 reporting line cell. 
When the two solutions were mixed together a white precipitate appeared. The solution 
was kept under mild shaking for 24 hr at 37°C (until the white precipitate is solubilized) 
then 100 µl of potassium acetate buffer 1 M pH 4 were added to the solution with 0.173 
mg of NaCNBH3 for 4 hours. All the solutions were prepared in endotoxin free water 
from Lonza.  
 
Purification of the Conjugated RrgB-TLR7aR 
 
The crude reaction mixture was purified to eliminate the unreacted TLR7aR with 
immobilized metal affinity chromatography (IMAC); 300 µl of a “ready to use” IMAC 
 
 
 
uncharged resin from Biorad were loaded with 350 µl of the crude reaction mixture. The 
IMAC resin was washed once with 300 µl of a 20% ethanol solution in PBS and 
discharged, afterwards it was eluted 4 times with 300 µl of a 300mM imidazole solution 
in PBS and the eluates were collected together. The total recovered eluate was then 
concentrated with an Amikon 30K spin filter used at 14 kRPM for 25 minutes at room 
temperature. The final recovered volume was 120 µl and was stored at -20°C. 
 
Analytical characterization 
 
SDS-PAGE was run using NuPAGE Bis-Tris 4-12% Precast Gel from Invitrogen in 
MOPS 1x buffer from Biorad. HiMark12™ unstained standard from Life technology 
was used and the loaded amount was 1.5 µg for each sample. Size exclusion UPLC (SE-
UPLC) analysis was performed with a ClassH bio-compatible system, equipped with a 
titanium cell. Waters BEH 200 column of 4.6*150 mm was chose and a KPi 100 mM / 
KCl 50 mM pH 7.2 buffer was used as mobile phase; flow was set at 0.35 ml/min, 
column temperature 40°C, sample temperature 4°C, sample injected volume 5 µL. 
Apparent molecular weight calculation was done against calibration curve obtained with 
gel filtration protein standards from Biorad; a value of r
2 
> 0.98 was obtained. 
Dynamic laser scattering measurement (DLS) was performed using a Z-sizer nano 
instrument from Malvern, using a 50 µL “use and throw” cuvette. Measurements were 
performed in back-scattering mode with a detector at 173° in triplicate. Automatic 
measurement modality was chosen and data analysis was performed using the protein 
 
 
 
analysis fitting model. Protein refractive index 1.450, disperdent viscosity 0.9181 cP 
and refractive index 1.332. equilibration time 60 seconds at 25°C. 
Protein titer was measured with MicroBCA assay using reagents from Thermoscientific. 
Endotoxins titer was measured with a plate kinetic chromogenic test using LONZA 
LAL reagents.  
Reverse phase UPLC (RP-UPLC) analysis was performed with a binary UPLC system 
from Waters equipped with a PDA detector (=214nm) using a BEH 300 C18 column 
of 2.1*50 mm, mobile phases were: A) water/TFA 0.1% and B) acetonitrile/TFA 0.1%, 
flow 0.5 ml/min; column  temperature 60°C, sample temperature 4°C and sample 
injection volume 2 µL. Gradient used for RrgB and RrgB-TLR7aR were: B% 0 to 3 min 
from 10 to 30 %, 3 to 20 min from 30 to 80 %, plus 2 minutes of equilibration time, 
method LOQ 0.05 µg/ml (for RrgB). Gradient for TLR7aR was: B% from 10 to 100 in 
2 min plus 1.5 min of equilibration time; flow 1.2 ml/min, column temperature 45°C, 
injection volume 10 µL sample temperature 4°C, detection  = 268 nm, method LOQ 
0.03 µg/ml and r
2
>0.99. 
 
 
Estimation of the conjugation rate 
 
Fluorimetric quantization of the amount of TLR7aR conjugated to RrgB was performed 
with a Tecan Infinite 200 plate reader fluorimeter, using 96 black walls plate; excitation 
 = 368 nm and emission  = 492 nm. Six standards were chose to obtain a linear 
 
 
 
calibration curve and analyzed in triplicate (r
2 
> 0.98). The sample was properly diluted 
to give fluorescence intensity within the calibration curve outers. 
 
Vaccine formulations 
 
Formulations have been prepared using the “sequential adsorption method” as describe 
from Matheis et al. (Matheis, Zott et al. 2001). Alum (aluminum hydroxide internally 
produced) at a stock concentration of 14.62 mg/ml in NaCl 2,2 g/l was used to have a 
final concentration of 2 mg/ml. Alum was then added with histidine buffer 100 mM pH 
6.5 to a final concentration of histidine of 10 mM, then sodium chloride 2M to a 
theoretical osmolality of 300 mOsm/Kg. After the addition of those excipients, the 
antigen or the antigen followed by the TLR7aNR was added (TLR7aNR was an 
analogue of TLR7aR without the reactive moiety). The formulations were diluted with 
water to the final required concentration for an injected volume of 100 µL. Alum dose 
and injection volume was chose according as previously described (Vecchi, Bufali et al. 
2012). The formulations were incubated over night at 4°C under mild shacking and used 
for mice immunization the day after.  
 
 
 
 
 
 
 
Vaccine formulations characterization 
 
An aliquot of 50 µL was used to measure its pH and osmolality with Osmomat 300 
autosampler equipped from Gonotec: pH was 7±0.5 and osmolality 300±60 mOsm/kg, 
compatible with a physiological i.p. administration. An aliquot of 100 µL was assayed 
for endotoxin content with a plate kinetic chromogenic test using LONZA LAL reagents 
at 1:10000 dilution folds. Another aliquot of 100 µL of vaccine formulations was spun 
down at 17 kRCF for 10 minutes at room temperature. The supernatant was used for 
antigen and for TLR7aNR quantification. RrgB and TLR7aNR were quantified with 
RP-UPLC meanwhile for RrgB-TLR7aR MicroBCA assay from Thermoscientific was 
preferred. 
The alum pellet was desorbed over night at 37°C under mild shacking with potassium 
phosphate buffer 500 mM pH 9, then spun down at 17 kRCF for 10 minutes at room 
temperature. The recovered supernatant was assayed for antigen and TLR7aNR content 
with the above describe techniques.  
 
Immunizations 
 
Protocols were reviewed and approved by the Novartis Vaccines and Diagnostics 
Institutional Review Committee. Six-week-old, speciﬁc-pathogen-free female BALB/c 
mice from Charles River were immunized intraperitoneally on days 0, 14, 28 with a 
 
 
 
volume of 100 µL of vaccine formulations.  At day 42 samples of sera were obtained 
from each animal. At day 43, each mouse was challenged intraperitoneally with a mean 
dose of 160 CFU of S.pneumoniae TIGR4 variant (it was considered as LD100 refereed 
to PBS). Blood bacteremia was evaluated 24 hours after challenge and mortality course 
monitored for 10 days as reported (Gianfaldoni, Censini et al. 2007). The animals were 
euthanized when they exhibited defined humane end points that had been pre 
established for the study in agreement with Novartis Animal Welfare Policies. 
 
Specific IgG measurement using protein-coupled 
microspheres 
 
A Luminex assay was developed to determine antibody titers in mouse antisera. In 
detail, 20 μg of recombinant protein were coupled to the carboxyl groups of 2.5 million 
MicroPlex microspheres (Luminex Corp), according to the manufacturer's instructions. 
The coupling reaction was confirmed by incubating 5000 antigen coupled microspheres 
with 8 serial two-fold dilutions of a hyper immune antiserum used as standard solution. 
To determine sera titers, the beads were incubated with mouse specific sera (dilution 
1:10000 in PBS), washed twice in 200μl of PBS and then incubated with PE conjugated 
secondary antibodies (1:200, Jackson Immuno Research) for 15 min in the dark onto an 
orbital shaker. The measurement of specific IgG content toward recombinant RrgB 
clade I and for RrgB-TLR7aR was done at a working concentration of 3500 beads per 
colour per well. IgG measurements were determined on the Luminex 200 analyzer using 
 
 
 
the Bio-Plex Manager 5.0 software (Bio-Rad, Hercules, CA). All results are expressed 
as Relative Luminex Units per ml (RLU/ml). The correlation of mean fluorescent 
intensity (MFI) units to RLU/ml of Ag-specific IgG was made by interpolating the MFI 
data through the standard solution. The lower limit of quantification was 0.32 RLU/ml 
for RrgB. 
 
Opsonophagocytosis Killing Assay (OPKA)  
 
OPKA was performed as described in Harfouche, Filippini et al. (Harfouche, Filippini 
et al. 2012). In brief, heat inactivated mice pooled sera were initially diluted 1:20 and 
tested in a 3-fold dilution in a reaction mixture consisting of Streptococcus pneumoniae 
TIGR4 strain, 12% rabbit complement, and differentiated HL-60 cells (bacteria:cells 
ratio, 1:400). After 1h of incubation at 37°C with 5% CO2, phagocytosis was stopped 
and an aliquot of the reaction mixture was tilt plated on TH Agar (Todd Hewitt) and 
incubated overnight. Bacteria survival was detected by colony counter ProtoCOL 
(Synbiosis). Results were expressed as percentage of killing or titer. The first was 
calculated as the percentage of bacteria that were killed in samples with bacteria-
phagocytes-active complement plus sera (BPC’+S), compared to bacteria-phagocytes-
active complement (BPC’). The titer was obtained interpolating the mean of the six 
replicate killing values and expresses the sera concentration at which the 50% of killing 
occurred. 
 
 
 
 
Statistical analysis 
IgG titer, bacteremia and mortality course were analyzed with the Mann-Whitney One-
tailed or two-tailed tests to compare immunized groups with the control group or each 
other, respectively. Opsonophagocytosis killing titers were analysed using 2-samples t 
test on log values (base 3). Values of p ≤ 0.05 were considered and referred to as 
significant. Minitab Software from Minitab Inc. was used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
Conjugation and purification of RrgB-TLR7aR 
We focused our attention on the creation of a covalent bound between the RrgB lysines 
and the TLR7aR; to achieve this results a 2-amino-4-oxy-benzaldehyde reactive moiety 
was linked to the TLR7 agonist. That moiety was able to give in a slightly acid 
environment an immine derivative that was reduced with sodium cyanoborohydride to 
obtain the desiderate conjugate. That moiety allows the conjugation of the TLR7aR with 
several different macromolecules that contain an amine group, like a peptide or a 
nucleic acid (Fig.7). Reaction temperature was set at 37°C, below the protein’s melting 
point (75°C). 
The histidine tag on RrgB provided a quick and efficient purification method to remove 
the unreacted TLR7aR that otherwise could react with the lysine of the animal tissues 
and rise an effect due to the free TLR7aR and not only to the co-localization of TLR7 
agonist and antigen. 
 
. 
Fig.7 Conjugation reaction scheme for the TLR7aR. The reaction has been conducted at 
37°C in acetate buffer 750mM pH=4.After 24hr from the adding of RrgB, sodium 
cyanoborohydride was added for other 4hr, then the crude reaction mixture was 
purified. 
 
 
 
Analytical characterizations of RrgB-TLR7aR 
 
SDS-PAGE was used to give a qualitative evidence of the increased molecular weight 
and the distribution of the conjugate; RrgB-TLR7aR had a smeared band higher than the 
native RrgB (Fig.8).  
 
 
Fig.8 SDS-PAGE of the conjugate RrgB-TLR7aR.  
M = MWs ladder; 1 = RrgB-TLR7aR; 2 = native RrgB 
 
Complementary with SDS-PAGE, a SE-UPLC analysis was performed and it confirmed 
the proteins’ distribution and the absence of detectable aggregates (Fig.9). 
 
 
 
 
Fig.9 Size Exclusion Ultra Performance Liquid Chromatography analysis 
Monomeric RrgB1.948 min; Natural RrgB aggregate 1.768 min; 
Conjugate RrgB-TLR7aR 1.689 min   
 
The average molecular weight of 130 kDa was estimated against calibration curve 
(Tab.1). 
 
 
 
Tab.1 Apparent molecular weights estimation from SE-UPLC analysis 
 
 RP-UPLC reinforced the observation made about the species distribution and estimates 
the composition of the RrgB-TLR7aR. The amount of unconjugated RrgB was lower 
than 20% of the total species (fig.10).  
Rt % Area Apparent MW (KDa)
Conj 1,689 100 130
Native 1,768 2,64 110
1,948 97,36 65
 
 
 
 
 
Fig. 10 Reverse Phase Ultra Performance Liquid Chromatography analysis. a) Native 
RrgB, b) TLR7aR, c) crude reaction mixture, d) purified reaction mixture 
 
DLS analysis cross-validated the observed features on the conjugate giving information 
on population distribution by measurement of the peaks polydispersity (PdI) (Tietz, 
Aldroubi et al. 1991). As expected, an increase of species’ size after conjugation was 
observed in the scattered light intensity representation. RrgB had a PdI=15% according 
to a narrow disperse population of macromolecules with hydrodinamic radius of 
4.05±0.55 nm, whereas the analysis of RrgB-TLR7aR gave a PdI=35 % with a 
hydrodynamic radius of 5.4±0.4 nm, 1.35 nm bigger than RrgB (this value was 
 
 
 
statistically significant); the higher value of PdI showed a polydisperse population 
composed of macromolecules with a wide distribution (Fig.11). 
 
Fig.11 Dynamic laser scattering analysis for the Light Intensity representation.  
Black peak native RrgB, green peak conjugated RrgB-TLR7aNR 
 
Fluorimetric quantization allowed the estimation of an average conjugation ratio 
RrgB:TLR7aR. The value of 1:44 led to calculate of the average molecular weight of 
131 kDa for RrgB-TLR7aR, agreeing with the apparent molecular weight calculated 
from SE-UPLC (Fig.12).  
 
Fig.12 Calibration curve for fluorimetric quantization of TLR7aR. 
Excitation wavelength 389 nm and emission 492 nm 
 
 
 
Formulations’ analytical characterizations 
RrgB-TLR7aR was alum formulated to be compared with a formulation of the same 
dose of Ag and TLR7; unfortunately due to the reactivity of a not reactive analogue 
(TLR7aNR) was used to compare its activity. 
Mice were immunized with the following formulations 1)PBS 2)RrgB (2 µg/dose), 
3)RrgB (0.2 µg/dose), 4)RrgB-TLR7aR (0.2 µg/dose), 5)RrgB+TLR7aNR (0.2 µg/dose 
+ 0.08 µg/dose). 
Formulations 4 and 5 contains the same amount of Ag and TLR7 agonist, they 
differentiate from how the TLR7 agonist is delivered (through antigen conjugation or 
simple formulation). 
Formulations were characterized for components adsorption, through supernatant and 
desorbed alum pellet analysis; adsorption was higher than 90% (Fig. 13, 14.15) (Tab.2). 
Formulations’endotoxin level was lower than 5 EU/ml. 
 
 
Fig. 13 RP-UPLC gradient for the organic phase variation for TLR7aR and calibration 
curve for standard samples of TLR7aR 
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Fig.14 RP-UPLC gradient for the organic phase variation for RrgB and RrgB-TLR7aR 
and calibration curve for RrgB standard samples 
 
 
 
Fig. 15 Calibration curve of MicroBCA for RrgB-TLR7aR 
 
 
 
Tab.2 Formulations composition characterization 
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Groups Composition Supernatant (µg/ml) Not adsorbed % Desorbed (µg/ml) Adsorbed %
1 PBS n.a. n.a. n.a. n.a.
2 RrgB 2µg / alum 0,26±0,01 1,29 18,68±0,03 93,41
3 RrgB 0,2µg / alum 0,08±0,01 3,99 1,96±0,03 97,76
4 RrgB-TLR7aR 0,2µg /alum 0,07±0,01 3,50 1,94±0,01 97,15
5 RrgB 0,2µg + TLR7aNR 0,08µg /alum 0,03±0,00 3,87 0,78±0,01 98,00
 
 
 
In vivo model 
Six-week-old, speciﬁc-pathogen-free female BALB/c mice from Charles River were 
immunized intraperitoneally on days 0, 14, 28 with a volume of 100 µL of vaccine 
formulations (Fig.16).  At day 42 samples of sera were obtained from each animal. At 
day 43, each mouse was challenged intraperitoneally with a mean dose of 160 CFU of 
S.pneumoniae TIGR4 variant that was considered as LD100. Blood bacteremia was 
evaluated 24 hours after challenge and mortality course monitored for 10 days as 
reported. In addition OPKA was measured for antibodies functionality. 
 
 
Fig.16 Schematic representation of the in vivo model 
 
 
 
 
Antibodies titer 
After the 3
rd
 immunization, sera were collected at day 42 and IgG titers were measured 
by Luminex assay (Fig. 17). RrgB-TLR7aR gave a 3 times higher IgG titer than group 
immunized with RrgB+TLR7aNR. The conjugated protein gave comparable titer as 2 
µg of RrgB and gave a 6 time higher IgG titer than 0.2 µg of RrgB. When the dose of 
0.08 ug of TLR7aNR was administered with RrgB, it showed no adjuvant effect in 
terms of IgG stimulation and the titer was comparable with the corresponding amount of 
RrgB alone. 
The increase of the IgG titer from RrgB-TLR7aR in comparison to mice that received 
the physical mixture RrgB+TLR7aNR was clearly due to the co-localization Ag and 
TLR7 agonist, which enhanced the immune response. 
The level of IgG produced was comparable to a 10 fold higher dose of native RrgB, so 
the conjugation effect led to an Ag dose reduction. 
Interestingly the dose of 0.08 µg of TLR7aNR administered to animals of group 5 was 
ineffective as adjuvant in term of IgG enhancement (tab.3). 
 
 
 
 
 
 
Fig.17 Median IgG titers with error bars measurement using protein coupled-
microspheres (Luminex® technology) for the conjugate RrgB-TLR7aR in comparison 
to the physical mixture (RrgB + TLR7aNR) and the native unconjugated RrgB from 8 
mice sera per each group 14 days after the 3
rd
 immunization. RLU stands for Relative 
Luminex Units. p values: * < 0.05; **<0.005; ns non-significant statistical difference.  
 
 
Tab.3 p values for IgG titers of immunized groups 
 
Bacteremia 
At day 43 each vaccinated group was infected with a dose of 160 CFU of S.pneumonie 
i.p. injected (equal to the LD100) and after 24 hours blood bacteremia was measured 
(Fig. 18).The RrgB-TLR7aR gave a 3.5 fold lower bacteremia than group vaccinated 
with the mixture of RrgB+TLR7aNR and gave comparable CFU counts as 2 µg of 
RrgB. RrgB+TLR7aNR gave a comparable bacteremia as the group vaccinated with 0.2 
µg of RrgB without the TLR7 agonist; these groups gave analogous CFU count as mice 
immunized with PBS . IgG are protective against pathogen proliferation, therefore the 
bacteremia showed the expected trend observed in the antibodies measurement (tab.4). 
Groups 1 2 3 4 5
1 ref 0,0003 0,0003 0,0002 0,0009
2 ref 0,0017 0,3960 0,0027
3 ref 0,0019 0,2470
4 ref 0,0091
 
 
 
 
 
Fig.18 Median blood bacteremia with error bars measured from 8 mice per each group 
at day 43 (24 hours after lethal challenge with 160 CFU of S.pneumoniae TIGR4 variant 
i.p. administred) expressed as log10 of the CFUs/ml for the conjugate RrgB-TLR7aR in 
comparison to the physical mixture (RrgB + TLR7aNR) and the native unconjugated 
RrgB. p values: * < 0.05; **<0.005; ns non-significant statistical difference.  
 
 
Tab.4 p values for blood bacteremia values of immunized groups 
 
Survival 
Mice immunized with 0.2 µg of RrgB-TLR7aR after challenge had a median life of 9.5 
days, with a residual survival at the end of the observation period of 50% as the animal 
Groups 1 2 3 4 5
1 ref 0,0006 0,0014 0,0005 0,0157
2 ref 0,0490 0,9575 0,0086
3 ref 0,0330 0,0661
4 ref 0,0067
 
 
 
treated with RrgB at 2 µg per dose (Fig.19). Animals vaccinated with RrgB+TLR7aNR 
had a median survival of 1.5 days, as the group immunized with RrgB at 0.2 µg per 
dose. They exhibited a comparable residual survival of 10 and 30% respectively. 90% 
of the animal that received PBS died at the 1
st
 day, the remaining 10% died the day after 
(Tab.5). 
 
 
 
Fig.18 Kaplan-Meier plot for survival estimation of the immunized groups for 10 days 
after lethal challenge. 8 mice were immunized per each group for the conjugate RrgB-
TLR7aR in comparison to the physical mixture (RrgB + TLR7aNR) and the native 
unconjugated. 
 
Survival conclusive confirmed the observed trends from IgG titer and bacteremia. 
 
Tab.5 Median values for survival of immunized groups 
Groups Composition Median of survival
1 PBS 1,5
2 RrgB 2 ug / alum 9,0
3 RrB 0,2 ug / alum 2,0
4 RrgB-TLR7a 0,2 ug / alum 9,5
5 RrrgB 0,2 ug + TLR7a 0,08 ug / alum 1,5
 
 
 
 
Tab.6 p values for median survival of immunized groups 
 
Opsonophagocytosis killing assay 
 
Post 3 antisera were tested in 6 replicates through in vitro OPKA to assess functionality 
of antibodies raised in BALB/c mice (Fig. 19). When TIGR4 was incubated with 
antisera, antibodies were able to kill the bacteria in a concentration dependent manner in 
immunized groups. Sera of animals immunized with PBS was not able to kill 
pneumococci (titer <80), differently from the other four groups tested. The RrgB-
TLR7aR gave a killing titer of 4210, statistically different from the one observed in 
RrgB+TLR7aNR (titer 218). RrgB at 2 µg dose and RrgB-TLR7aR at 0.2 µg showed a 
non significant different killing titer (11365 and 4402 respectively). Similarly, no 
significant difference was observed between RrgB at 0.2 µg dose and RrgB+TLR7aNR 
(titer 498 and 218 respectively) antisera (tab. 7).  
Groups 1 2 3 4 5
1 ref 0,0283 0,0962 0,0020 0,5371
2 ref 0,0600 0,7343 0,0500
3 ref 0,0600 0,4008
4 ref 0,0166
 
 
 
 
Fig.19 Median with error bars of the opsonophagocytosis killing titers for the 
immunized groups obtained from 8 mice per each group. Results are the mean of six 
replicate and expresses the sera concentration at which the 50% of killing occurred for 
the conjugate RrgB-TLR7aR in comparison to the physical mixture (RrgB + TLR7aNR) 
and the native unconjugated. p values: * < 0.05; **<0.005; ns non-significant statistical 
difference. 
 
 
 
Tab.7 p values for median OPKA titers of immunized groups 
 
 
 
 
Groups 1 2 3 4 5
1 ref 0,0000 0,0001 0,0000 0,0000
2 ref 0,0120 0,3010 0,0020
3 ref 0,0390 0,6970
4 ref 0,0060
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
The chemical behavior of proteins makes bioconjugation reactions difficult to modulate 
to control the conjugation ratio and the selectivity. Using bifunctional linker or 
conjugant with highly reactivity moiety the aggregation of the bioconjugate can increase 
as the product heterogeneity, as can happen with an UV-induced conjugation reaction 
(Wille-Reece, Flynn et al. 2005). 
Aminoacids can undergo into different degradation pathways, the more sensitive are 
tryptophan (Fig.20), tyrosine (fig.21), phenylalanine (fig.22) and cysteine (fig.23). 
 
 
 
Fig.20 Triptophan light induced degradation 
 
 
 
 
 
Fig.21 Tyrosine light induced degradation 
 
 
 
Fig.22 Phenylalanine light induced degradation 
 
 
 
 
 
Fig.23 Cysteine light induced degradation 
 
This work was conducted with the aim to adjust a mild and reproducible conjugation 
approach for a TLR7 agonist and characterize the conjugate. 
Reaction’s conditions were developed to enhance protein’s reactivity, lowering the 
amount of free antigen in the final product, and achieve the highest conjugation ratio. 
The high number of exposed lysines allowed this model protective antigen to achieve a 
high derivatization ratio, which led to a high loading capacity, plus its unfolding 
temperature and good temperature stability provided the possibility to screen several 
reaction conditions. 
 
 
 
The requirements needed for a good model protective antigen were selected based on 
chemical and biological features. For this purpose, the antigen needed to have an 
available structure characterization, ready availability with sufficient purity (higher than 
80%), high solubility, known chemical and physical stability properties.  
The requirements needed for a good model antigen were selected based on chemical and 
biological features. For this purpose, the antigen needed to have an available structure 
characterization (i.e. resolved X-rays and known conformation) (fig.24), to evaluate 
different conjugation approaches, ready availability and sufficient purity (higher than 
80%), high solubility, known chemical and physical stability properties.  
 
 
 
Fig.24 Full resolved structure of RrgB 
 
 
 
As biological requirements we focused our attention on the availability of an in vivo 
model with established and defined readouts that were able to give a robust data panel 
about immunogenicity, antibody functionality and protection against challenge.  
After a screening of different antigens, we chose RrgB from the pilus of 
S.pneumoniae(LeMieux, Hava et al. 2006) because it has all the chemical 
(Hilleringmann, Giusti et al. 2008; Spraggon, Koesema et al. 2010; El Mortaji, 
Contreras-Martel et al. 2012) and biological (Barocchi, Ries et al. 2006; Gianfaldoni, 
Censini et al. 2007; Gentile, Melchiorre et al. 2011; Moschioni, De Angelis et al. 2012) 
requirements desiderated. 
Streptococcus pneumoniae is the major cause of invasive pneumococcal disease and 
kills over 1.5 million children per year (http://who.int/vaccines/en/pneumococcus.shtml) 
and the actual vaccination strategy is based on two types of polysaccharide vaccines. 
One is composed of 23 purified capsular polysaccharides from the bacteria (Pneumovax 
23®) (Teele, Klein et al. 1981) and the other one is composed of polysaccharides 
conjugated to the carrier protein CRM197 (Prevenar®, a glycoconjugate vaccine) (Black, 
Shinefield et al. 2000). These vaccines are serotype dependent and the lack of the actual 
prophylactic strategy is a serotype-independent one, able to counteract the serotype 
redistribution by strains not covered by the actually licensed vaccines (Spratt and 
Greenwood 2000), therefore a protein-based vaccines could overcome this problem. 
The ideal protein candidate would be a surface exposed protein, common to all 
serotypes, this perfect antigen has yet to be found but some promising proteins have 
been already discovered (Barocchi, Censini et al. 2007). The possibility to increase 
RrgB immunogenicity through the effect of the TLR7 agonist conjugation could lead to 
a more promising vaccine candidate than the native protein alone and open the 
 
 
 
possibility to develop a serotype independent vaccine with a lower complexity than the 
ones actually licensed 
The low differences in molecular weights between RrgB and the various species of 
RrgB-TLR7aR did not allowed a selective purification approach as for glycoconjugates 
(Bardotti, Averani et al. 2008), therefore the amount of residual RrgB was ~20% of the 
total species. 
The tested dose of 0.2 µg of RrgB-TLR7aR contained ~0.03 µg of RrgB; because the 
effect of 0.2 µg of RrgG was almost ineffective, so is improbable that the contribution 
of 0.03 µg contributed to the observed effects. 
RrgB-TLR7aR was characterized with two high sensitive orthogonal techniques as SE-
UPLC and DLS, so we can definitely demonstrate that no aggregates are in the 
conjugate. 
An elegant work from Kastenmüller et al. (Kastenmuller, Wille-Reece et al. 2011) 
demonstrated how the aggregation enhance and maximize the effect of a conjugate 
OVA-TLR7/8 to promote optimal antigen acquisition and presentation by multiple DCs 
subsets in the proinflammatory cytokines fashion and this led to a potent Th1 CD4
+
 and 
CD8
+
 T cell response. This effect was able to give a significant decrease in the bacterial 
load after challenge with Listeria monocytogenes expressing OVA in liver and spleen. 
That work agreed with the results obtained with the aggregate Gag protein from Wille-
Reece (Wille-Reece, Flynn et al. 2005; Wille-Reece, Wu et al. 2005). Unfortunately, 
aggregation is not a very reproducible phenomena, and in some cases, even if the 
amount of aggregates is the same for different batches, the type of arrayed structures 
can be very broad (Rosenberg 2006), reducing the consistency between batches and 
increase the variability of the observed immune response.  
 
 
 
The study of Kastenmüller supported the observation made with the UV-catalyzed 
conjugate used from Wille-Reece (Wille-Reece, Flynn et al. 2005; Wille-Reece, Wu et 
al. 2005). The UV-irradiation had some inevitable limitations, in terms of 
reproducibility and selectivity. Some aminoacid can be photoxidated (Kerwin and 
Remmele 2007) and the protein can be affected by an UV-induced aggregation that can 
lead to an increased immunogenicity (Rosenberg 2006); moreover the UV exposure can 
change the TLR7 agonist structure too. Due to these potential issues we used a mild 
conjugation approach as the reductive ammination reaction. 
Previous works (Gianfaldoni, Censini et al. 2007; Gentile, Melchiorre et al. 2011) 
demonstrated that RrgB needs to be formulated with alum to give protection against 
lethal challenge of S.pneumoniae; we observed that RrgB-TLR7aR gives no IgG 
production if is not alum formulated (Fig.25), therefore RrgB was selected as model 
protective antigen to test the impact of the formulation contemporary with the co-
localization. 
 
 
 
 
 
Fig.25 Effect of alum adsorption on the conjugate RrgB-TLR7aR. Median IgG titers 
with error bars obtained with protein coupled-microspheres measurement from 8 mice 
per each group sera 14 days after the 3
rd
 immunization. RLU stands for relative luminex 
units. p values: ** < 0.005; ***<0.0005. 
 
This study is aimed to make a direct comparison of the Ag and the adjuvant when they 
are conjugate and sequentially formulated; this comparison can show the different 
impact on the immune response of how the Ag and the TLR7 agonist are presented to 
the DCs. To definitely observe the effect of the co-localization Ag and TLR7 agonist, 
RrgB-TLR7aR was evaluated against the same amount of Ag and TLR7 agonist; for this 
reason the formulation of RrgB-TLR7aR/Alum contains an equivalent dose of Ag and 
TLR7 agonist as RrgB+TLR7aNR/alum.  
The agreeing observations made from Abs measurement, bacteremia and survival were 
also supported also by in vitro analysis, to assess antibodies functionality though 
opsonophagocitosys killing assay (OPKA). When the serum from RrgB 2 µg/dose of 
was compared with the one from RrgB-TLR7aR, the antibodies functionality was not 
statistically different and an equal functional response could be achieved also using a 10 
fold lower dose of antigen, through the conjugation of the TLR7 agonist to the Ag. 
Moreover, OPKA demonstrates that the functionality of antibodies is enhanced through 
conjugation in respect to the mixture RrgB+TLR7aNR. This assay highlighted the 
evidences from the protection assay that no functional epitopes were damage or masked 
from the bioconjugation reaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
Bioconjugation reactions lead to a distribution of species that can be very complex 
because of the high number of the equivalent surface exposed aminoacids that can be 
modified and the potential loss of conformation. Therefore,  the conjugate was fully 
characterized with orthogonal techniques that allowed a detailed evaluation of species 
distribution, conjugation ratio, integrity and aggregation status (Stephanopoulos and 
Francis 2011). 
The present study was developed to evaluate the effect of co-localization of Ag-TLR7 
agonist and its impact on protection with a non-aggregated conjugate synthesized using 
mild, controlled and reproducible reaction conditions.  
The RrgB-TLR7aR was tested in a mouse model that correlated protection and blood 
bacteremia to the IgG titre, via to the known protective effect of antibodies against the 
pathogen infection (Musher 1992). 
The possibility to increase the immunogenicity through TLR7 agonist conjugation led to 
a more promising vaccine candidate than the native protein alone and opens up the 
possibility of developing a serotype independent vaccine with a lower complexity than 
those currently licensed (Spratt and Greenwood 2000). 
The rational for the observed effect presumably relies on the co-localization of Ag and 
TLR7 agonist, which is a more effective delivery system than their simple co-
administration (Blander 2007). Co-localization can avoid the systemic dispersion of 
proinflammatory cytokines enabling the TLR7 agonist and the Ag to target the same 
dendritic cell at same time. It seems possible that the systemic immune activation via 
TLR signalling does not create a local cytokine and chemokine gradient that is optimal 
to mobilise immune cells to the site of infection, so conjugation can overcome this 
problem. This has been demonstrated by Wu et al. using an OVA conjugate that 
 
 
 
enhanced mice survival following infection with B.antracis spores. In that specific case 
protection was due to an aspecific immune stimulation, which could be translated into a 
more potent and highly specific response when the TLR7 agonist was conjugated to the 
protective antigen (Wu, Hayashi et al. 2007).  
The conjugation induced a specific response that may be enhanced by a synergistic 
effect of the alum formulation. In the studied case, the use of RrgB led to a 10 fold dose 
reduction and allowed the immune system to recognize a very low dose of TLR7 
agonist, which if it was only formulated resulted ineffective.  
The synergistic effect of conjugation can lead to an increase in IgG production, reducing 
the adjuvant and antigen dose required whilst increasing potency and safety in 
comparison to the native antigen. Further investigations will need to be accomplished to 
fully exploit its potentialities and the possibility to synthesize active conjugates, without 
the need to be aggregated, will lead to a more reproducible drug substance and increases 
the potentiality for a scale up of this technology on other vaccine’s candidates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aluminum adjuvants dose guidelines in 
vaccines formulation for pre-clinical 
evaluations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Current use of aluminium adjuvants 
 
 
 
 
 
 
 
 
 
 
 
The use of insoluble mineral salts as adjuvants commenced at the beginning of the 
twentieth century and ever since its licensure, aluminum based suspensions have been 
most commonly used in a large variety of human and veterinary vaccines. Despite this 
broad application, there is still a poor understanding not only in terms of mechanism of 
its action, but also in the physico-chemical properties in relation to the interaction with 
antigen(s) and/or perturbation of protein antigen structure.(Braun, Clapp et al. 2011; 
Mbow, De Gregorio et al. 2011)  
Some guidelines of tolerated aluminum salts doses are available for clinical research, 
but there are no clear definitions of dose limits for the preclinical research use.  
One of the earliest uses of potassium alum (Al(SO4)2*12H2O)  as a vaccine adjuvant 
was reported by Glenny et al. in 1926.(Glenny, Pope et al. 1926) The investigators 
demonstrated that the addition of potassium alum to diphtheria toxoid produced an 
insoluble compound and depending on the added amount of potassium alum, the 
remaining filtrate no longer contained the toxoid. When the precipitated diphtheria 
toxoid was injected into guinea pigs it resulted in a higher antigenic response in 
comparison to the fluid toxoid. 
Since then, aluminum salts have been broadly licensed and the long history of record of 
clinical data in a large spectrum of age population supports an excellent safety profile 
and a limited reactogenicity in muscle tissues.  
Regulatory agencies define antigen adsorption percentage on the mineral adjuvant and 
aluminum dose for humans, but there are no clear definitions for limits for both 
veterinary vaccines and preclinical research grade formulations. European Medicines 
Agency has developed a general guideline for preclinical research, but it does not 
express aluminum adjuvant limits.(Use 2005) Here we are we are aiming to give a 
 
 
 
rationale for the calculation of aluminum doses in small animal studies at the different 
stages of pre-clinical research, from early antigen selection to vaccine optimization and 
preclinical development.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aluminium salts adjuvants 
 
 
 
 
 
 
 
 
 
 
 
When a solution of aluminum chloride is slowly added to a solution of potassium 
hydroxide in a buffered environment, a precipitate colloid is obtained and this can be 
purified to give aluminum oxyhydroxyde (AlOOH, also known as boehmite).(Gupta, 
Rost et al. 1995) This compound has a crystalline structure with an average adsorption 
surface of 500 m²/g.(Johnston, Wang et al. 2002)  
 
 
 
Fig. 26 Transmission electron microscopy for aluminium oxyhydroxyde (left) and 
aluminium phosphate (right) 
 
 
 
 
Fig. 27 X-ray diffraction pattern of aluminum hydroxide adjuvant 
 
 The precipitated material is a gel composed of particles ranging between 3 and 15 µm, 
with an average diameter of 10 µm.(Gupta, Rost et al. 1995)  The aggregation index and 
polydispersity of aluminum adjuvant depends on several manufacturing parameters; 
even if manufacturers use the same pH controlled precipitation procedure, different 
product profiles can be obtained (in terms of aggregation/polydispersity), e.g. with a 
different stirring speed or a different reaction vessel geometry.The second most 
commonly used aluminum salt in vaccines is aluminum phosphate, a complex 
heterogeneous salt with the general formula Al(OH)x(PO4)y where the ratio of phosphate 
(PO4) and aluminum (Al) is in the range of 0.88-1.0, and the mean particle size is 2 µm, 
depending on the pH of preparation procedure.(Burrell, Johnston et al. 2000; Burrell, 
Johnston et al. 2000) The primary particles are plates having a diameter of 
 
 
 
approximately 50 nm.The primary particles form loose, irregular aggregates of 1 to 10 
µm. The aggregates are easily dissociated by the shear associated with mixing but re-
form readily when the shear is removed.(White and Hem 2000; Hem and Esch 
2007)The preparation protocol is similar to the one described earlier where potassium 
phosphate is used instead of potassium hydroxide. The precipitate is an amorphous 
material with counter ions inclusions.(Lindblad and Schonberg 2010) Like aluminum 
hydroxide, aluminum phosphate adjuvant is a gel as well but with a lower adsorptive 
surface (250 m²/g).(Glemza, Parent et al. 1992) Other aluminum adjuvants like double 
aluminum salts (i.e. KAl(SO4)2*12H2O)  are also prepared by co-precipitation of 
aluminum chloride and potassium sulfate  at a neutral pH and used in vaccines such as 
tetanus and diphtheria toxoids vaccine Decavac. More soluble aluminum salts have 
other uses and are listed in pharmacopeias as oral antacid compounds due to their ability 
to react with hydrogen ions in the stomach. 
Aluminum based adjuvants are prepared to have the rheological properties of a 
Newtonian gel where the viscosity does not change with the shear stress applied and can 
be easily injected with a syringe. This is achieved by controlling pH, ionic strength, 
temperature, mixing and addition speed of reagents, in order to avoid the formation of 
undesired interferences (i.e. inclusion of amorphous material in the crystals or random 
crystallization within the amorphous product).  
Aluminum adjuvanted vaccines can be prepared by either antigen co-precipitation with 
aluminum salts or antigen adsorption onto preformed aluminum salt gels. The first 
method has a great historical relevance in the development of adjuvanted vaccines such 
as the diphtheria vaccine. However, the co-precipitation procedure gives formulations 
with low reproducibility and high variability in the immunological response. Antigen(s) 
 
 
 
addition to preformed aluminum gels is generally the preferred option in the pre-clinical 
evaluation of model vaccine antigens. The latter procedure is preferred due to ease of 
screening, reproducibility and induction of consistent immune responses.(Gupta and 
B.E. 2000)   
Alum has different mechanisms of action, and they are not fully comprehended still. 
The dilution of the vaccine preparation into the muscle interstitial fluid (MIF) results in 
an array of potential agonists of the immune cascade (a), including:(1) Al3+(aq); (2) 
free antigen (AG); (3) particulate adjuvant (ADJ); (4) ADJ with associated AG; (5) AG-
Al complex; (6) MIF ligand-Al complex; (7) ADJ with associated MIF ligand; (8) MIF 
ligand-AG complex; (9) particulate iron (as contaminant of adjuvant) either free or with 
adsorbed Al/AG and resultant reactive oxygen species (ROS); (10) ADJ with associated 
MIF ligand-AG complex; (11) ADJ with associated MIF ligand-Al complex. MIF 
ligands might include biomolecules such as; ATP, albumin, transferrin, citrate, 
fibrinogen. (b) The array of agonists act upon a number of cell types including, the 
resident muscle tissue (potentially causing necrotic and/or apoptotic cell death) 
andinfiltrating innate cells such as, monocytes (potential for AlADJ-induced 
differentiation to dendritic cells), granulocytes (potential for AlADJ-induced 
eosinophilia acting directly on B cells), macrophages (are known to persist for long 
periods close to the injection site and may be characterized by inclusions of AlADJ) and 
dendritic cells (DC). The latter may be the major antigen presenting cell (APC). (c) 
There are myriad possible modes of interaction between agonists and innate cells 
including; (i) toll-like receptor (TLR) binding of AG2, AG-Al complex5, MIF ligand-
AG complex8, Al3+(aq) ; (ii) multiple TLR binding of AG-ADJ4; (iii) phagocytosis of 
ADJ3, AG-ADJ4, MIF ligand-ADJ7, MIF. 
 
 
 
 
 
 
Fig.28 Alum possible mechanisms of action 
 
 
 
 
 
 
 
 
 
Aluminium dose limits recommendations 
and conversion factors 
 
 
 
 
 
 
 
 
 
The complex chemical structure of aluminum salts and the gel-like morphology do not 
allow for a direct quantification. The elemental Al content is generally determined via 
indirect methods such as the complexometric titration of Al
3+
 with EDTA upon sample 
dissolution, the ion-coupling plasma analysis or the atomic adsorption analysis. The 
values can be then converted into a nominal concentration of aluminum salts 
considering the corresponding minimal formulas, as reported in Tab. 8.  
 
 
Tab.8 Conversion table for aluminium adjuvants 
 
US Code of Federal Regulations recommends that the amount of aluminum permitted in 
a single unit human dose of vaccine should not exceed 0.85 mg of Al
3+
 per dose if the 
level is assayed, or 1.14 mg if determined by calculation on the basis of the amount of 
aluminum compound added in the preparation. The regulations were last amended in 
1981 to increase the permissible level of aluminum to 1.25 mg in biological products, 
consistently with the WHO and European standards per single human dose of a product 
as well (Tab. 9).  
 
mg AlOOH mg Al(OH)3 mg AlPO4 mg AlK(SO4)2*12H2O
1 mg Al3+ 2,220 2,890 4,533 17,630
 
 
 
 
Tab.9 Maximum dose allowed of aluminium adjuvants 
 
If different aluminum compounds other than aluminum oxyhydroxyde and aluminum 
phosphate are used (i.e. double aluminum salts), the total amount of total aluminum salt 
should not be more than the permitted equivalent amount expressed as potassium alum 
(e.g. 15 mg of potassium alum correspond to 1.25 mg of aluminum). The limits were 
empirically selected from safety data, adjuvanticity and the risk/benefit ratio. The levels 
of aluminum salts can be higher if demonstration of efficacy is proven.(Wolf, Kaplanski 
et al. 2010)  
As already mentioned herewith, there is no defined maximum limit for the allowed 
content of aluminum adjuvants in veterinary vaccines and this is normally set from a 
balance between efficacy and local reactogenicity as demonstrated from many licensed 
vaccines (tab.10) 
EU
1.25 mg Al3+ 0.85 mg Al3+ (Assayed) 1.14 mg (calculated)
mg AlOOH 2,778 1,889 2,535
mg Al(OH)3 3,613 2,457 3,296
mg AlPO4 0,000 0,000 5,153
mg AlK(SO4)2*12H2O 22,044 14,990 20,037
FDA
 
 
 
 
Tab.10 Aluminium amount in licensed vaccines 
 
 
 
 
 
 
 
Trade Name Manufacter ug Al dose mg Al per dose mols Al mg Al(OH)3 mg AlPO4
Childhood Vaccine
DtaP Infanrix GSK 625 0,625 0,023 1,808
Certiva NAVA 500,00 0,500 0,019 1,447
Acelimmune Wyeth 230,00 0,230 0,009 0,665
Tripedia Sanofi Aventis 170,00 0,170 0,006 0,492
DTP Avaxim Sanofi Aventis 300,00 0,300 0,011 0,868
Boostrix GSK 500,00 0,500 0,019 0,576 2,260
Hib conj Liq Pedvax Hib Merck 225,00 0,225 0,008 0,651
Pneumo conj Prevenar Wyeth 125,00 0,125 0,005 0,565
DTP-Hib Tetramune Wyeth 850,00 0,850 0,032 2,459
HBV/Hib Recombivax B Merck 225,00 0,225 0,008 0,651
HPV Engerix B GSK 250,00 0,250 0,009 0,723
DT Anatetall Novartis 58,00 0,058 0,002 0,168
Adult Vaccine
HPV Cervarix GSK 500,00 0,500 0,019 1,447
HBV Fendrix GSK 500,00 0,500 0,019 2,260
HAV Harix GSK 250,00 0,250 0,009 0,723
VAQTA Merck 450,00 0,450 0,017 1,302
Lyme Lymerix GSK 500,00 0,500 0,019 1,447
Tickborne encephalitis virus Ticovac Masta 170,00 0,170 0,006 0,492
HBV/HAV Twinrix GSK 450,00 0,450 0,017 0,576 2,034
Rabies RabAvert Novartis 442,00 0,442 0,016 1,279
 
 
 
 
 
 
 
 
What is an acceptable dose of aluminium 
adjuvant for pre-clinical evaluation? 
 
 
 
 
 
 
 
 
 
 
 
Many experiments have been performed during the last several years to better 
understand if an average human dose of aluminum adjuvant has an impact on 
tolerability in preclinical species. Flarend et al. demonstrated that 0.85 mg of Al
3+
 in the 
form of aluminum oxyhydroxyde or aluminum phosphate injected intramuscularly in 
rabbits lead neither to a significant aluminum systemic exposure nor to an acute toxic 
effect.(Flarend, Hem et al. 1997) In a pharmacokinetic study, the authors showed that 
aluminum phosphate gives a three fold higher area under the curve (AUC) for a 28 days 
serum Al
3+
 concentration profile respect to aluminum oxyhydroxyde.  Most likely, the 
crystalline structure of aluminum oxyhydroxyde is more resistant to dissolution in 
interstitial fluids in comparison to the amorphous aluminum phosphate. Even if 
aluminum phosphate gives higher systemic exposure, the increase of Al
3+
 concentration 
in the plasma from a 0.85 mg dose of aluminum adjuvant (maximum allowed human 
dose) was only 2 ng/ml with both adjuvants respect to the base levels of 30 ng/mL in 
rabbits. The increased level corresponds to 0.071 ng/ml*day, which does not induce an 
acute toxic effect. In a rat acute toxicology study,(Titkov and Oganesyan 1995) animals 
were treated intramuscularly with aluminum chloride and the LD50 (lethal dose able to 
kill 50% of the animals) was found to be 400 mg/kg, i.e. 36.42 mg of Al
3+
, 29 times or 
42 times higher than the maximum allowed dose in humans in Europe or in USA 
respectively. 
Even if still controversial, preclinical data on protective immunity indicate that antigens 
and adjuvants must be delivered together to achieve an enhancement in immunogenicity 
and protection. From a physico-chemical perspective, the adsorption of recombinant 
protein antigens results in both stabilization and extension of formulation shelf life in 
most of the cases. Regardless of the strength of antigen-aluminum salt interactions that 
 
 
 
may play a role in immunogenicity,(Hansen, Sokolovska et al. 2007) protein antigen 
adsorption onto aluminum salts should be generally considered beneficial and the 
formulation optimization should aim ideally to a 100% adsorption of each vaccine 
component. Adsorption onto an aluminum-containing adjuvant is generally required in 
order to potentiate the immune response, generally true for recombinant protein antigens 
unless there is a tight binding like in the case of the Hepatitis B antigen. The HBsAg 
antigen has a high adsorptive coefficient and a low degree of elution from aluminum 
oxyhydroxyde and this has a detrimental effect in the in vivo immunogenicity when 
compared to a formulation where the aluminum oxyhydroxyde is pretreated with 
phosphate and the adsorptive coefficient is lowered.(Hansen, Belfast et al. 2009) Even 
when formulations were specifically designed to avoid antigen adsorption and found to 
be immunogenic in vivo, a degree of association was suggested based on the confocal 
microscopy analyses evidencing entrapment of proteins in void spaces within the 
adjuvant aggregates.(Romero Méndez, Shi et al. 2007) In preclinical studies, the 
concentration of aluminum salt should already consider the minimum dose required to 
obtain at least 70-80% adsorption (or association) for each antigen. If more than one 
protein antigen is used in the vaccine formulation, an alternative way to ensure a 
complete and long lasting adsorption is to use the “separate adsorption 
procedure”.(Matheis, Zott et al. 2001) In this procedure antigens can be adsorbed 
individually under optimal controlled conditions. Upon complete adsorption, the single 
antigen/aluminum formulations can be combined in one final formulation.  
Starting from an indicative 0.85 mg dose of Al
3+
  that correspond to the maximum dose 
of approved human vaccines (Tetramune
®
, Wyeth Fig.29) a scaling down of aluminum 
adjuvant should be considered and the adsorption of the same amount of antigens 
 
 
 
should be verified. The factor to take into account for scaling down would be simply the 
ratio of volume of human vaccine and the maximum allowed animal injection volume 
.(Brito and Singh 2011)  
 
Fig.29  Tetramune vaccine (DT, TT, aP, Hib alum adsorbed) from Wyeth (ex Lederle) 
 Taking rodents as the elected species for formulation optimization studies and 
considering a 100 μL as a standard injection volume, the scale-down factor is 5 and the 
dose of Al
3+
 becomes 0.17 mg , which represents the maximum dose to begin with 
(Tab.11). 
 
Tab.11 Recommended injection volumes 
The suggested range of aluminum adjuvant in rodent animal model is therefore 150±20 
µg of Al
3+
 in 100 µl of vaccine final formulation (150 µg of Al
3+ 
correspond to 333 µg 
Model body weight (kg) dose (ml/hr)
Mouse 0,03 0.050-0.200
Rat 0,45 0.050-0.200
Rabbit 4 0.100-0.500
Monkey 8 0.100-0.500
Baboon 12 0.100-0.500
 
 
 
of aluminum oxyhydroxyde or 680 µg of aluminum phosphate). The adsorption of each 
antigenic component in the desired combination needs to be verified in a titration of 
Al
3+
 dose from the maximum suggested (150 µg) to at least 10 fold less (15 µg). The 
maximum suggested dose can reasonably ensure an adsorption percentage of 80% or 
more for each antigen in the final formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
The principle of scaling down a human aluminum dose for preclinical species is driven 
first by tolerability and the use of the minimum required adjuvant dose that is necessary. 
However, no significant toxicity has been observed by several researchers with a scaled 
down human dose of aluminum based vaccine in preclinical species. Aluminum salts 
are effective and safe adjuvants in animal models, from early antigen screening through 
vaccine development with no major concerns on adverse effects. 
Antigen adsorption is the second and the most fundamental parameter to consider in 
aluminum concentration selection for vaccines based on single or multiple protein 
components. A prediction of adsorption of proteins on aluminum based adjuvants is 
possible on the basis of parameters such as isoelectric point of antigens, buffer 
composition, required antigen loading, and total binding capacity of the aluminum salt 
employed. The adjuvanted formulation should be designed to get the proper adsorption 
level, pH and osmolality. A dose of 150 µg of Al
3+ 
is suggested especially in case of 
early antigen screening where information on adsorptive capacity of proteins on 
aluminum based adjuvants may not be available. Full physico-chemical characterization 
should lead to the selection of aluminum concentration at a later stage and the minimum 
required dose to ensure an 80% adsorption on all components should be considered. The 
in vivo profiling of adjuvanted vaccines with titration of aluminum is then fundamental 
for an in depth understanding of the relationship between formulation and immune 
response in the preclinical animal model to support selection of Al
3+
 dose for clinical 
advancement. 
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